Expression and use of anti-CD20 Antibodies

Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C424S143100, C424S144100, C424S155100, C424S153100, C424S156100, C424S172100, C424S174100, C530S388220, C530S388730, C530S388800, C530S388850, C530S867000

Reexamination Certificate

active

07744877

ABSTRACT:
Disclosed herein are methods of depleting peripheral blood B cells in a human host comprising administering to the host an immunologically active anti-CD20 antibody in an amount effective to deplete peripheral blood B cells in the host.

REFERENCES:
patent: 4831175 (1989-05-01), Gansow
patent: 4975278 (1990-12-01), Senter et al.
patent: 5099069 (1992-03-01), Gansow
patent: 5124471 (1992-06-01), Gansow
patent: 5246692 (1993-09-01), Gansow
patent: 5286850 (1994-02-01), Gansoh
patent: 5439665 (1995-08-01), Hansen
patent: 5460785 (1995-10-01), Rhodes
patent: 5500362 (1996-03-01), Robinson et al.
patent: 5595721 (1997-01-01), Kaminski
patent: 5648267 (1997-07-01), Reff
patent: 5677180 (1997-10-01), Robinson et al.
patent: 5686072 (1997-11-01), Uhr et al.
patent: 5693780 (1997-12-01), Newman et al.
patent: 5721108 (1998-02-01), Robinson et al.
patent: 5736137 (1998-04-01), Anderson
patent: 5776456 (1998-07-01), Anderson
patent: 5843398 (1998-12-01), Kaminski et al.
patent: 5843439 (1998-12-01), Anderson
patent: 6015542 (2000-01-01), Kaminski et al.
patent: 6090365 (2000-07-01), Kaminski et al.
patent: 6120767 (2000-09-01), Robinson et al.
patent: 6183744 (2001-02-01), Goldenberg
patent: 6287537 (2001-09-01), Kaminski et al.
patent: 6306393 (2001-10-01), Goldenberg
patent: 6399061 (2002-06-01), Anderson
patent: 6455043 (2002-09-01), Grillo-López
patent: RE38008 (2003-02-01), Abrams
patent: 6565827 (2003-05-01), Kaminski et al.
patent: 6652852 (2003-11-01), Robinson et al.
patent: 6682734 (2004-01-01), Anderson
patent: 6893625 (2005-05-01), Robinson et al.
patent: 2002/0009444 (2002-01-01), Grillo-Lopez
patent: 2002/0197255 (2002-12-01), Anderson et al.
patent: 2003/0021781 (2003-01-01), Anderson et al.
patent: 2003/0026804 (2003-02-01), Grillo-Lopez
patent: 2003/0082172 (2003-05-01), Anderson et al.
patent: 2003/0095963 (2003-05-01), Anderson et al.
patent: 2003/0147885 (2003-08-01), Anderson
patent: 2003/0206903 (2003-11-01), Grillo-Lopez
patent: 2004/0167319 (2004-08-01), Teeling
patent: 2004/0213784 (2004-10-01), Grillo-Lopez et al.
patent: 2005/0163708 (2005-07-01), Robinson et al.
patent: 2005/0186205 (2005-08-01), Anderson et al.
patent: 2006/0034835 (2006-02-01), Adams
patent: 0 125 023 (1984-11-01), None
patent: 0 125 023 (1984-11-01), None
patent: 0 173 494 (1986-03-01), None
patent: 0 274 394 (1988-07-01), None
patent: 0 274 394 (1988-07-01), None
patent: 0 682 040 (1995-11-01), None
patent: 0 682 040 (1995-11-01), None
patent: 0 451 216 (1996-01-01), None
patent: 0 669 836 (1996-03-01), None
patent: 0 752 248 (1997-01-01), None
patent: 0 125 023 (2002-03-01), None
patent: 87/ 02671 (1987-05-01), None
patent: WO 88/04936 (1988-07-01), None
patent: 89/ 00999 (1989-02-01), None
patent: WO 91/04320 (1991-04-01), None
patent: WO 92/07466 (1992-05-01), None
patent: WO 93/02108 (1993-02-01), None
patent: WO 94/11026 (1994-05-01), None
patent: 00/ 09160 (2000-02-01), None
patent: 00/ 27428 (2000-05-01), None
patent: 00/ 27433 (2000-05-01), None
patent: 01/ 10460 (2001-02-01), None
patent: 2004/ 056312 (2004-07-01), None
Badger, et al. “Experimental Radioimmunotherapy of Murine Lymphoma with131I-labeled Anti-T-Cell Antibodies.” Cancer Research, 46, pp. 6223-6228, 1986.
Buchsbaum, et al. “Improved Delivery of Radiolabeled Anti-B1 Monoclonal Antibody to Raji Lymphoma Xenografts by Predosing with Unlabeled Anti-B1 Monoclonal Antibody.” Cancer Research; 52, pp. 637-642, 1992.
Chen, et al. “Tumor Idiotype Vaccines. VI. Synergistic Anti-Tumor Effects with Combined “Internal Image” Anti-Idiotypes and Chemotherapy.” Journal of Immunology, 143, pp. 1053-1057, No. 3, 1989.
Clark et al, “Role of the Bp35 cell surface polypeptide in human B-cell activation.” Immunobiology, vol. 82, pp. 1766-1770, 1985.
Clark, et al. “Phase Evaluation of the Anti-Bp35 Antibody Induces Human B Cell Proliferation: Implications for in Vivo Immunotherapy.” Journal Cellular Biochemistry Supp. 9A, p. 63, 1985.
DeNardo, et al. “Fractionated Radioimmunotherapy of B-cell Malignancies with 131I-Lym-1.” Cancer Research (Suppl) 50, pp. 1014s-1016s, 1990.
Kaminski, et al. “Initial Clinical Radioimmunotherapy Results with131-I-Anti-B1 (Anti-CD20) in Refractory B-Cell Lymphoma.” Antibody Immimoconjugates, and Radiopharmaceuticals vol. 5, No. 3 p. 345, 1992.
Kaminski, et al. “131-I Anti-B1: Initial Clinical Evaluation in B-Cell Lymphoma.” Third Conference on Rid and Rit of Cancer, Abstract. No. 144, 1990.
Langmuir, “Radioimmunotherapy: Clinical Results and Dosimetric Considerations.” Nuclear Medicine Biology vol. 19, No. 2, pp. 213-225, 1992.
Levy, et al. “Tumor Therapy with Monoclonal Antibodies.” Federation Proceedings 42:9 pp. 2650-2656, 1983.
Macklis, et al. “Radiobiologic Sutdies of Low-Dose-Rate90Y-Lymphoma Therapy.” Cancer Supplement, vol. 73, No. 3, pp. 966-973, 1994.
Maloney, et al. “Monoclonal Anti-Idiotype Antibody Therapy of B-Cell Lymphoma: The Addition of a Short Course of Chemotherapy Does Not Interfere with the Antitumor Effect Nor Prevent the Emergence of Idiotype-Negative Variant Cells.” Blood, vol. 80, No. 6, pp. 1502-1510, 1992.
Masucci, et al. “Chemotherapy and Immunotherapy of Colorectal Cancer.” Medical Oncology Tumor Pharmacother vol. 8, No. 3, pp. 207-220, 1991.
Nadler, et al. “A Unique Cell Surface Antigen Identifying Lymphoid Malignancies of B Cell Origin.” Journal of Clinical Investigative, vol. 67, pp. 134-140, 1981.
Reilly, “Radioimmunotherapy of malignancies.” Clinical Pharmacy, vol. 10, pp. 359-375, 1991.
Press, et al. Scientific Proceedings, ASCO, Abstrict No. 864, 1986.
See-Lasley, et al. “Hodgkin's Disease and Non-Hodgkin's Lymphoma Nitrogen mustard, vincristine (Oncovin), procarbazine, and prednisone (MOPP).” Manual of Oncology Therapeutics, C.V. Mosby Company, pp. 44-71, 1981.
Senter, et al. “Enhancement of the in vitro and in vivo Antitumor Activities of Phosphorylated Mitomycin C and Etoposide Derivatives by Monoclonal Antibody-Alkaline Phosphatase Conjugates.” Cancer Research 49, pp. 5789-5792, 1989.
Stashenko, et al. “Characterization of Human B Lymphocyte-Specific Antigen.” The Journal of Immunology vol. 125, No. 4, pp. 1678-1685, 1960.
Chinn, et al. “Production and characterization of radiolabeled anti-CD20 monoclonal antibody: potential application to treatment of B-cell lymphoma.” Proceedings of the American Medical Association for Cancer Research, vol. 33, Abstract 2012, p. 337, 1992.
Classon, et al. “The Primary Structure of the Human Leukocyte Antigen CD37, A Species Homologue of the Rat MRC OC-44 Antigen.” The Journal of Experimental Medicine, vol. 169, No. 4, pp. 1497-1502, 1989.
DeNardo, et al. “Requirements for a Treatment Plan in System for Radioimmunotherapy.” International Journal of Radiation Oncology Biology Physics, vol. 11, No. 2, pp. 335-348, 1985.
Kaminski, et al. “Radioimmunotherapy (RIT) of Refractory B-Cell Lymphoma with 131-I-Anti-B1 (Anti-CD20) Antibody: Promising Early Results Using Non-Marrow Ablative Radiation Doses.” Blood, Abstract 161, p. 162.
Langmuir, “Radiommunotherapy: Clinical Results and Dosimetric Considerations.” Nuclear Medicine and Biology, vol. 19, No. 2, pp. 213-225, 1992.
Larson, et al. “Comparison of Bone Marrow Dosimetry and Toxic Effect of High Dose131I-labeled Monoclonal Antibodies Administered to Man.” Nuclear Medicine and Biology, vol. 16, No. 2, pp. 153-158, 1989.
Leichner, et al. “Tumor dosimetry in radioimmunotherapy: Methods of calculation for beta particles.” Medical Physics, vol. 20, No. 2, Pt.2, pp. 529-534, 1993.
Leichner, et al. “Dosimetry and Treatment Planning in Radioimmunotherapy.” Frontiers of Radiation Therapy and Oncology, vol. 24, pp. 109-120, 1990.
Link, et al. “A Unique Antigen on Mature B-Cells Defined by a Monoclonal Antibody.”

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Expression and use of anti-CD20 Antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Expression and use of anti-CD20 Antibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Expression and use of anti-CD20 Antibodies will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-4243969

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.